doi: 10.1056/NEJMc2103740. Epub 2021 Apr 7.
Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351
Affiliations
- PMID:33826819
- PMCID: PMC8063884
- DOI: 10.1056/NEJMc2103740
Item in Clipboard
Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351
Xiaoying Shen et al. N Engl J Med..
Display options
Format
Display options
Format
No abstract available
Figures
Convalescent serum samples were obtained from infected persons 1 to 8 weeks after resolution of coronavirus disease 2019 infection or 2 to 10 weeks after the most recent positive SARS-CoV-2 test. Serum samples were obtained from recipients of the Moderna vaccine on day 57 (28 days after the second vaccine dose), and Novavax serum samples were obtained from vaccine recipients on day 35 (14 days after the second vaccine dose). Results are shown as the difference in neutralization titers of matched samples (Panels A and B) and the difference in titers relative to the D614G variant (the ratio of titers against the variant indicated) for each sample set (Panel C). Lower values indicate stronger cross-neutralization of the variant virus. Dashed thin lines in Panels A and B represent individual samples, and thick black lines represent the geometric means of each sample group, as indicated at the right. Thick black bars in Panel C represent the geometric mean titer differences for the sample sets, which are also labeled above each set. Circles in Panel C represent the differences in titers relative to D614G for individual samples. P values for the comparison of the reciprocal neutralization titers at 50% inhibitory dilution (ID50) and 80% inhibitory dilution (ID80) are pairwise comparisons of the data shown in Panels A and B, calculated with the use of the Wilcoxon signed-rank test. P values less than 0.001 correlate to Q (adjusted P) values less than 0.0019 (see Table S2 in Supplementary Appendix 2). Differences in the neutralization titers among the three sample sets shown in Panel C were not significant (P>0.05 by the Wilcoxon rank-sum test).
Similar articles
- Susceptibility of Circulating SARS-CoV-2 Variants to Neutralization.Wang GL, Wang ZY, Duan LJ, Meng QC, Jiang MD, Cao J, Yao L, Zhu KL, Cao WC, Ma MJ.Wang GL, et al.N Engl J Med. 2021 Jun 17;384(24):2354-2356. doi: 10.1056/NEJMc2103022. Epub 2021 Apr 6.N Engl J Med. 2021.PMID:33822491Free PMC article.No abstract available.
- Standardised neutralising antibody assays are needed for evaluating COVID-19 vaccines.Wang Y.Wang Y.EBioMedicine. 2021 Nov;73:103677. doi: 10.1016/j.ebiom.2021.103677. Epub 2021 Nov 3.EBioMedicine. 2021.PMID:34742128Free PMC article.No abstract available.
- Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine.Wu K, Werner AP, Koch M, Choi A, Narayanan E, Stewart-Jones GBE, Colpitts T, Bennett H, Boyoglu-Barnum S, Shi W, Moliva JI, Sullivan NJ, Graham BS, Carfi A, Corbett KS, Seder RA, Edwards DK.Wu K, et al.N Engl J Med. 2021 Apr 15;384(15):1468-1470. doi: 10.1056/NEJMc2102179. Epub 2021 Mar 17.N Engl J Med. 2021.PMID:33730471Free PMC article.Clinical Trial.No abstract available.
- Variants of SARS-CoV-2, their effects on infection, transmission and neutralization by vaccine-induced antibodies.Wahid M, Jawed A, Mandal RK, Dailah HG, Janahi EM, Dhama K, Somvanshi P, Haque S.Wahid M, et al.Eur Rev Med Pharmacol Sci. 2021 Sep;25(18):5857-5864. doi: 10.26355/eurrev_202109_26805.Eur Rev Med Pharmacol Sci. 2021.PMID:34604978Review.
- COVID-19: Structural Considerations for Virus Pathogenesis, Therapeutic Strategies and Vaccine Design in the Novel SARS-CoV-2 Variants Era.Volkan E.Volkan E.Mol Biotechnol. 2021 Oct;63(10):885-897. doi: 10.1007/s12033-021-00353-4. Epub 2021 Jun 18.Mol Biotechnol. 2021.PMID:34145550Free PMC article.Review.
Cited by
- In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains.Diamond M, Chen R, Winkler E, Case J, Aziati I, Bricker T, Joshi A, Darling T, Ying B, Errico J, Shrihari S, VanBlargan L, Xie X, Gilchuk P, Zost S, Droit L, Liu Z, Stumpf S, Wang D, Handley S, Stine W, Shi PY, Garcia-Knight M, Andino R, Chiu C, Ellebedy A, Fremont D, Whelan S, Crowe J, Purcell L, Corti D, Boon A.Diamond M, et al.Res Sq [Preprint]. 2021 Apr 23:rs.3.rs-448370. doi: 10.21203/rs.3.rs-448370/v1.Res Sq. 2021.Update in:Nature. 2021 Aug;596(7870):103-108. doi: 10.1038/s41586-021-03720-y.PMID:34013259Free PMC article.Updated.Preprint.
- Refocus on Immunogenic Characteristics of Convalescent COVID-19 Challenged by Prototype SARS-CoV-2.Huang X, Liang C, Li M, Chen H, Li Z, Ruan Q, Hu X, Zeng L, Lin H, Zhao W, Xiao J, Sun L, Sun J.Huang X, et al.Vaccines (Basel). 2023 Jan 4;11(1):123. doi: 10.3390/vaccines11010123.Vaccines (Basel). 2023.PMID:36679968Free PMC article.
- A potent alpaca-derived nanobody that neutralizes SARS-CoV-2 variants.Weinstein JB, Bates TA, Leier HC, McBride SK, Barklis E, Tafesse FG.Weinstein JB, et al.iScience. 2022 Mar 18;25(3):103960. doi: 10.1016/j.isci.2022.103960. Epub 2022 Feb 22.iScience. 2022.PMID:35224467Free PMC article.
- Aerosol Transport Modeling: The Key Link Between Lung Infections of Individuals and Populations.Darquenne C, Borojeni AAT, Colebank MJ, Forest MG, Madas BG, Tawhai M, Jiang Y.Darquenne C, et al.Front Physiol. 2022 Jun 20;13:923945. doi: 10.3389/fphys.2022.923945. eCollection 2022.Front Physiol. 2022.PMID:35795643Free PMC article.Review.
- Carbohydrate fatty acid monosulphate: oil-in-water adjuvant enhances SARS-CoV-2 RBD nanoparticle-induced immunogenicity and protection in mice.Nanishi E, Borriello F, Seo HS, O'Meara TR, McGrath ME, Saito Y, Chen J, Diray-Arce J, Song K, Xu AZ, Barman S, Menon M, Dong D, Caradonna TM, Feldman J, Hauser BM, Schmidt AG, Baden LR, Ernst RK, Dillen C, Yu J, Chang A, Hilgers L, Platenburg PP, Dhe-Paganon S, Barouch DH, Ozonoff A, Zanoni I, Frieman MB, Dowling DJ, Levy O.Nanishi E, et al.NPJ Vaccines. 2023 Feb 14;8(1):18. doi: 10.1038/s41541-023-00610-4.NPJ Vaccines. 2023.PMID:36788219Free PMC article.
References
- Zhang W, Davis BD, Chen SS, Martinez JMS, Plummer JT, Vail E. Emergence of a novel SARS-CoV-2 strain in southern California, USA. January 20, 2021. (https://www.medrxiv.org/content/10.1101/2021.01.18.21249786v1). preprint. - PMC - PubMed
Publication types
MeSH terms
Substances
Related information
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous